scispace - formally typeset
N

Nora D. Volkow

Researcher at National Institute on Drug Abuse

Publications -  1038
Citations -  121498

Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.

Papers
More filters
Journal ArticleDOI

The Metabolic Centroid Method for PET Brain Image Analysis

TL;DR: The posterior and downward displacement of the mean metabolic centroid is consistent with the concepts of hypofrontality, hyperactivity of subcortical structures, and neuroleptic effect in schizophrenics.
Book ChapterDOI

Exploiting temporal information in functional magnetic resonance imaging brain data

TL;DR: It is demonstrated that incorporation of computer science principles into functional neuroimaging clinical studies, facilitates deduction about the behavioral probes from the brain activation data, thus providing a valid tool that incorporates objective brain imaging data into clinical classification of psychopathologies and identification of genetic vulnerabilities.
Journal Article

Metabolic studies of drugs of abuse.

TL;DR: Although still very preliminary, these studies exemplify how metabolic brain measurements can address questions of relevance in the investigation of drugs of addiction such as mechanisms of toxicity, addiction, withdrawal, and reinforcement of other drugs of abuse.
Journal Article

Monitoring the Brain's Response to Alcohol With Positron Emission Tomography.

TL;DR: Positron emission tomography data has been used to investigate possible mechanisms for some of alcohol 3s effects and to provide additional evidence for the heritability of alcoholism.
Journal ArticleDOI

Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease

TL;DR: In this article, the authors investigated the role of dopaminergic signaling in response inhibition in early stage Parkinson's disease and found that the PD group showed weaker striatal activations to salient events (infrequent vs. frequent events: stop vs. go trials).